2-year follow-up shows Jatenzo is effective, safe in men with hypogonadism

Ronald S. Swerdloff, MD, MACP, discusses 2-year follow-up data from an open-label, multicenter study of Jatenzo (testosterone undecanoate) oral capsules in men with hypogonadism. The findings showed that Jatenzo kept testosterone levels in the normal range with a similar safety profile as other testosterone replacement therapies (TRTs). Of note, Swerdloff says that over the 2 years, Jatenzo showed “no evidence of liver toxicity,” whereas some TRTs have been associated with liver toxicities.

Swerdloff is a senior investigator at the Lundquist Institute, chief, Division of Endocrinology, Harbor-UCLA Medical Center, and professor of Medicine, David Geffen School of Medicine at UCLA.